Navigation Links
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Date:1/16/2017

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2017 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that on January 3, 2017 and January 16, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 214,000 shares of common stock to four new employees. These awards were granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel granted stock options to purchase shares of Rigel's common stock to (i) three of the employees with an exercise price of $2.38 per share, the closing price of Rigel's common stock on December 30, 2016, the first trading date prior to January 3, 2017, the effective date of such grants and (ii) one employee with an exercise price of $2.51 per share, the closing price of Rigel's common stock on January 13, 2017, the first trading date prior to January 16, 2017 the effective date of such grant. The stock options vest as follows: certain of the shares of common stock subject to the award vest in equal monthly installments over a two period subject to the achievement of one or more performance conditions and certain of the shares of common stock subject to the award vest in equal monthly installments over a four year period, with one-fourth of the shares subject to the award vesting on the first anniversary of the vesting commencement date.

Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor in a number of indications. The company completed and reported results from two Phase 3 clinical studies of fostamatinib in chronic immune thrombocytopenia (ITP) in August and October 2016. Rigel is also conducting a Phase 2 clinical trial with fostamatinib in autoimmune hemolytic anemia (AIHA) and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-300391187.html


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer
2. Rigel Announces Fourth Quarter and Year End 2015 Financial Results
3. Rigel to Present at Cowen and Company 36th Annual Health Care Conference
4. Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
5. Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)
6. Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Rigel Announces Third Quarter 2015 Financial Results
8. Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results
9. Rigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders
10. Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
11. Rigel Announces Second Quarter 2015 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2019)... (PRWEB) , ... November 19, 2019 , ... ... management of hemophilia, which aims to ensure that members receive hemophilia drugs from ... that increases costs. Beginning in January of 2020, Highmark members will receive hemophilia ...
(Date:11/19/2019)... (PRWEB) , ... November 19, 2019 , ... Dr. David ... Surgery in Los Angeles. Carla's expertise in nonsurgical and body contouring procedures is ... CoolSculpting®. , " Carla is among an exclusive group of experts in ...
(Date:11/19/2019)... (PRWEB) , ... November 18, 2019 , ... “Comprehensive Vital ... Cell-lines”” by Alan J. Balmer has been named No. 1 International Best Seller on ... No. 1 Hot New Release in Cell Biology, Nosology, and Reference. , The ...
Breaking Medicine Technology:
(Date:11/16/2019)... ... 15, 2019 , ... At their 36th Annual Awards Gala on November 12th ... for programs and services benefiting Calvary patients and their families. Ryan Field, WABC-TV Sports ... The Chiffons, and Shirley Alston Reeves, original lead singer of The Shirelles. ...
(Date:11/16/2019)... ... November 15, 2019 , ... ... the United States, access to cannabis via well-managed dispensaries becomes more and more ... Business Plans, industry-leading online provider of state-of-the-art, online, custom cannabis business plans is ...
(Date:11/15/2019)... ... 2019 , ... Anxiety is sweeping the country in epidemic ... current figures of adults who suffer at 40 million, yet only 36.9% of ... different ways, including Post Traumatic Stress Disorder (PTSD), phobias, Generalized Anxiety Disorder (GAD), ...
(Date:11/15/2019)... ... November 15, 2019 , ... Spectrum Vision Partners claimed 13th ... Workplaces for 2019. The recently announced rankings honor those organizations where employees feel ... partnership with Energage to conduct surveys into organizational health and identify Long Island ...
(Date:11/14/2019)... ... November 14, 2019 , ... ... Loma Linda University International Heart Institute have performed a pioneering coronary intervention ... the axillary artery in the shoulder. The new procedure offers surgeons another option ...
Breaking Medicine News(10 mins):